Work

NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.4_suppl.296

Authors: Dean F. Bajorin, Padmanee Sharma, Leonard G. Gomella, Elizabeth R. Plimack, Peter H. O'Donnell, Jean H. Hoffman-Censits, Thomas W. Flaig, David I. Quinn, Robert Brownell Sims, Michael Locker, Nadeem A. Sheikh, Todd DeVries, Seth P. Lerner

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Sidney Kimmel Cancer Center, Fox Chase Cancer Center, University of Chicago, University of Colorado Denver, USC Norris Comprehensive Cancer Center, Dendreon (United States), Baylor College of Medicine

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591405622

Cites:

Cited by: 9

Related to: 10